Tarsus Pharmaceuticals(TARS)
$76.76+2.93 (+3.97%)
TARS
Tarsus Pharmaceuticals stock forecast
$76.76
At close:+2.93 (+3.97%)
Want to see TARS full AI Analyst Report?
Tarsus Pharmaceuticals (TARS) Stock Forecast & Price Target
298 Followers
TARS Analyst Ratings
Strong Buy
8Buy0Hold0Sell
Based on 8 analysts giving stock ratings to Tarsus Pharmaceuticals in the past 3 months
TARS Stock 12 Month Forecast
Average Price Target
$105.57▲(37.53% Upside)Based on 8 Wall Street analysts offering 12 month price targets for Tarsus Pharmaceuticals in the last 3 months. The average price target is $105.57 with a high forecast of $116.00 and a low forecast of $97.00. The average price target represents a 37.53% change from the last price of $76.76.
Past 12 Months12 Month ForecastJan2026Oct2026
High$116.00
Average$105.57
Low$97.00
Highest Price TargetHighest$116.00Average Price Target$105.57Lowest Price TargetLowest$97.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Jenna Davidner | Barclays | $110 | buy | 43.30%Upside | Reiterated | 11/11/26 | ||
| Graig Suvannavejh | Mizuho Securities | $94→$102 | buy | 32.88%Upside | Reiterated | 11/06/26 | ||
| Matthew Caufield | H.C. Wainwright | $88→$106 | buy | 38.09%Upside | Reiterated | 11/04/26 | ||
| Mazahir Alimohamed | Oppenheimer | $100→$103 | buy | 34.18%Upside | Reiterated | 11/04/26 | ||
| Jason Gerberry | Bank of America Securities | ― | buy | ― | Reiterated | 11/04/26 | ||
| Eddie Hickman | Guggenheim | $89→$97 | buy | 26.37%Upside | Reiterated | 11/04/26 | ||
| Andrea Newkirk | Goldman Sachs | $116 | buy | 51.12%Upside | Initiated | 09/24/26 | ||
| Dennis Ding | Jefferies | $105 | buy | 36.79%Upside | Reiterated | 09/08/26 | ||
| Lachlan Hanbury Brown | William Blair | ― | buy | ― | Reiterated | 08/12/26 | ||
| Francois Brisebois | LifeSci Capital | $104 | buy | 35.49%Upside | Assigned | 08/08/26 | ||
| Andreas Argyrides | Chardan Capital | $105→$98 | buy | 27.67%Upside | Reiterated | 04/24/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Jenna DavidnerBarclays | BuyReiterated$110 | 11/11/26 | 43.30%Upside | ||
| Graig SuvannavejhMizuho Securities | BuyReiterated$94→$102 | 11/06/26 | 32.88%Upside | ||
| Matthew CaufieldH.C. Wainwright | BuyReiterated$88→$106 | 11/04/26 | 38.09%Upside | ||
| Mazahir AlimohamedOppenheimer | BuyReiterated$100→$103 | 11/04/26 | 34.18%Upside | ||
| Jason GerberryBank of America Securities | BuyReiterated | 11/04/26 | ― | ||
| Eddie HickmanGuggenheim | BuyReiterated$89→$97 | 11/04/26 | 26.37%Upside | ||
| Andrea NewkirkGoldman Sachs | BuyInitiated$116 | 09/24/26 | 51.12%Upside | ||
| Dennis DingJefferies | BuyReiterated$105 | 09/08/26 | 36.79%Upside | ||
| Lachlan Hanbury BrownWilliam Blair | BuyReiterated | 08/12/26 | ― | ||
| Francois BriseboisLifeSci Capital | BuyAssigned$104 | 08/08/26 | 35.49%Upside | ||
| Andreas ArgyridesChardan Capital | BuyReiterated$105→$98 | 04/24/26 | 27.67%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Tarsus Pharmaceuticals
3 Months
Success Rate9/12 ratings generated profit
75%
Average Return
+14.48%
Copying Lachlan Hanbury Brown's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +14.48% per trade.
1 Year
Success Rate13/13 ratings generated profit
100%
Average Return
+49.68%
Copying Eddie Hickman's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +49.68% per trade.
2 Years
Success Rate19/19 ratings generated profit
100%
Average Return
+83.16%
Copying Jason Gerberry's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +83.16% per trade.
TARS Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 14 | 12 | 13 | 4 | 3 |
| Buy | 12 | 10 | 11 | 9 | 10 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 26 | 22 | 24 | 13 | 13 |
In the current month, TARS has received 13 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TARS average Analyst price target in the past 3 months is 105.57.
TARS Financial Forecast
High$0.14
Consensus$-0.28
Low$-0.59
TARS Earnings Forecast
Next quarter’s earnings estimate for TARS is -$0.28 with a range of -$0.59 to $0.14. The previous quarter’s EPS was -$14.40. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$214M
Consensus$211M
Low$203M
TARS Sales Forecast
Next quarter’s sales forecast for TARS is $210.76M with a range of $203.16M to $214.00M. The previous quarter’s sales results were $194.57M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
TARS Stock Forecast FAQ
What is TARS’s average 12-month price target, according to analysts?
Based on analyst ratings, Tarsus Pharmaceuticals’s 12-month average price target is $105.57.
What is TARS’s upside potential, based on the analysts’ average price target?
Tarsus Pharmaceuticals has 37.53% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TARS a Buy, Sell or Hold?
Tarsus Pharmaceuticals has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
What is Tarsus Pharmaceuticals’s price target?
The average price target for Tarsus Pharmaceuticals is $105.57. This is based on 8 12-month price targets, issued in the past 3 months. The highest analyst price target is $116.00, the lowest forecast is $97.00. The average price target represents a 37.53% increase from the current price of $76.76.
What do analysts say about Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Street analysts.
How can I buy shares of TARS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
